November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Dec 16, 2023, 18:18

SABCS23 Day 2 Highlights by Oncology Brothers

Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the second day’s highlights from X/Twitter.

SABCS23 Day 2 Highlights Community Oncology:

HR+
1. Update
CM7FL + KN756
2.
MONARCH3
3.
HER2CLIMB02 (Her2+)
4. Role of Anthracyclines
5.
OLAnzaPiNE (all solid tumors)

SABCS23 Day 2 Highlights by Oncology Brothers

1. CM7FL and KN756 PeriOp IO/NeoAdj chemo -> cut -> Adj IO in early HR+ Breast Cancer

 pCR mainly w/ N+ and low ER (how much does adj IO add in HR+ and TNBC? Adj IO w/ Atezolizumab in TNBC a  study),
– If correct
, use NeoAdj IO/Chemo then PARPi/CDK 4/6i in Adj? Sherene Loi.

For the more information click here.

SABCS23 Day 2 Highlights by Oncology Brothers

2. MONARCH3 8 year follow-up: Abemaciclib + AI vs AI in HR+ mBC 1L:

– ITT showed of higher 13.1mos OS with Abema (66.8 vs 53.7 mos) BUT statistical significant (HR: 0.804; 95% CI, 0.637-1.015; p=0.0664)  Now what?
– Ribo > Abema > Palbo?
For the more information click here.
SABCS23 Day 2 Highlights by Oncology Brothers
3. HER2CLIMB02: Tucatinib + TDM1 vs TDM1 in 2L Her2+ – mPFS 9.5 vs 7.4 mos (HR: 0.76),
– Brain Mets mPFS 7.8 vs 5.7 mos (HR: 0.64),
– now, potentially 3 options in 2L: TDxD, Tucatinib + TDM1, and Tucatinib + Cape + Trastuzumab.
For the more information click here.SABCS23 Day 2 Highlights by Oncology Brothers4. Use of Anthracyclines: Prior to SABCS, we discussed this article by Paolo Tarantino
Hal Burstein Borges, and Piccart,
– Use should be limited to TNBC and “considered” in small subset of Hr+.

For the more information click here.

SABCS23 Day 2 Highlights by Oncology Brothers

5. OLAnzaPiNE: low vs standard dose olanzapine in all Solid tumors using highly emetogenic chemo.

– Low dose (2.5mg) is non-inferior to standard dose (10mg),
– Improved AE (such as daytime somnolence).”

SABCS23 Day 2 Highlights by Oncology Brothers

Source: Oncology Brothers/X